Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tenofovir Exalidex in Renal Impairment
NCT03284164Phase 1Completed
- Sponsor
- Hepion Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir exalidex in hepatitis B (HBV) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hepion Pharmaceuticals. Primary endpoint: Pharmacokinetics of Tenofovir Exalidex. Started Sep 2017; status: completed.
02
Drugs
tenofovir exalidex
03
Conditions
hepatitis B (HBV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03284164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284164.